ABSTRACT
INTRODUCTION
Cancer chemotherapy is characterized by a wide variation in response among patients. This is due, in part, to pharmacokinetic variability. The most widely used strategy to decrease pharmacokinetic variability is to normalize a drug dose to the patient's body surface area. Because body surface area-based dosing strategies do not reduce interindividual variability in anticancer drug pharmacokinetics (1) , other measures to predict drug disposition and effects are needed. As cytochrome P-450 3A (CYP3A) is involved in the metabolism of ϳ50% of all prescribed drugs (2) , including many anticancer agents, phenotyping strategies to predict an individual's CYP3A activity before cytotoxic chemotherapy treatment is one approach for dose individualization. Various noninvasive in vivo probes for evaluating CYP3A activity have been described and several have been shown to correlate with drug clearance (3) . The most widely tested and accepted CYP3A probes are midazolam and erythromycin, although selection of the ideal CYP3A-phenotyping probe remains controversial (4, 5) .
Little is known regarding factors affecting CYP3A activity in cancer patients. Rivory et al. (6) noted an association between the inflammatory response and CYP3A activity, which was assessed with the erythromycin breath test, in 40 patients with advanced cancer. CYP3A activity was inversely correlated with both inflammatory markers C-reactive protein and ␣-1 acid glycoprotein, with the former accounting for 44% of interpatient variation. In the current study, the influence of patient characteristics, including age, body size, liver function and sex, the acute phase reactant ␣-1 acid glycoprotein, and CYP3A4 and CYP3A5 genotypes on CYP3A activity, as assessed with the erythromycin breath test, was explored in 134 patients with advanced cancer.
upper limit of normal. Patients with varying degrees of liver impairment were included in this study and grouped according to the following: liver function group 1, total bilirubin Ͻ 1.5ϫ upper limit of normal and no elevations in aspartate aminotransferase (AST), alanine aminotransferase (ALT), or alkaline phosphatase as described for groups 2, 3A, and 3B; liver function group 2, total bilirubin Ͻ1.5ϫ upper limit of normal, elevations in AST and/or ALT Ͼ 1.0ϫ upper limit of normal concurrent with alkaline phosphatase Ն 2.5ϫ upper limit of normal, or AST and/or ALT Ն 1.5ϫ upper limit of normal concurrent with alkaline phosphatase Ͼ 1.0ϫ upper limit of normal, or isolated elevations of AST and/or ALT or alkaline phosphatase Ն 5.0ϫ upper limit of normal; liver function group 3A, total bilirubin Ͻ 1.5ϫ upper limit of normal, concurrent elevations in AST and/or ALT Ն 1.5ϫ upper limit of normal concurrent with alkaline phosphatase Ն 2.5ϫ upper limit of normal; and group 3B, total bilirubin Ն 1.5ϫ upper limit of normal with any elevations in liver transaminases or alkaline phosphatase.
Patients were not eligible for the clinical trial conducted in Baltimore, Maryland, Washington, DC, and Rotterdam and Leiden, the Netherlands (study protocol 1) if they were concurrently taking phenytoin, carbamazepine, barbiturates, rifampin, phenobarbital, St. John's wort, and/or ketoconazole. Patients enrolled to the clinical trial in Sydney, Australia (study protocol 2) were not eligible if they were concurrently taking medications that were known to induce or inhibit CYP3A activity. The dose, frequency, and duration of all concomitant drugs were recorded. The clinical protocols were approved by the local institutional review boards (Baltimore, Maryland, Washington, DC, Rotterdam and Leiden, the Netherlands, and Sydney, Australia), and all patients provided written informed consent before enrollment.
Pretreatment evaluations included in this study were performance status, height, weight, and the following serum chemistries: serum creatinine, alkaline phosphatase, AST, ALT, total bilirubin, and ␣-1 acid glycoprotein. Body surface area was calculated with Mosteller's formula: body surface area ϭ [height (cm) ϫ weight (kg) Ϭ 3600] 0.5 (7) . Body mass index (BMI) was calculated with the formula: BMI ϭ [weight (kg)/ (height/100) 2 ]. Erythromycin Breath Test. For study protocol 1, the erythromycin breath test dose and collection balloons were obtained from Metabolic Solutions (Nashua, NH). The dose consisted of 0.04 mg of [ 14 C-N-methyl]-erythromycin, containing 3 Ci of radioactivity, dissolved in 4.5 mL of 5% dextrose solution. The dose was administered as an i.v. injection over ϳ1 minute. Breath samples were collected in balloons postinjection at 5, 10, 15, 20, 25, 30 , and 40 minutes. Samples were shipped to Metabolic Solutions for measurement of breath carbon dioxide. The data were reported as the flux of 14 CO 2 , expressed as a percentage of dose exhaled per minute at each collection time point assuming a CO 2 output of 5 mmol/min/m 2 body surface area (8) .
For study protocol 2, the erythromycin breath test was performed as described previously (9) . Briefly, 4 Ci of 14 Cerythromycin (55 mCi/mmol N-methyl- 14 C, NEN Life Science Products, Inc., Boston, MA) was administered as an i.v. injection, and breath samples were collected into gas-tight balloons (Pytest, Ballard Medical Products, UT) postinjection at 5, 10, 15, 20, 25, 30 and 40 minutes. Breath samples were processed by bubbling the collected gas through a capture solution consisting of hyamine hydroxide 10ϫ (Packard, Sydney, New South Wales, Australia) in 50:50 (v/v) methanol:etomidate to which a trace of phenolphthalein was added. After the addition of scintillation solution (Ultima Gold, Packard) and counting, the data were reported as the flux of 14 CO 2 , expressed as a percentage of dose exhaled per minute, at each collection time point assuming a CO 2 output of 5 mmol/min/m 2 body surface area (8) .
The conventional erythromycin breath test parameter, the flux at 20 minutes (C 20min ) was the observed value. The area under the flux curve from time zero to 40 minutes (AUC 0 -40min ) was determined with the linear trapezoidal method. The erythromycin breath test parameter, 1/T max , was determined as described previously (9, 10) . A monoexponential equation was fitted to the percent dose 14 C exhaled/min-time data, and the time of the maximum percent dose 14 C exhaled/min (T max ) was estimated. For some patients, the profiles had not reached a maximum and were still increasing at 40 minutes. In these cases, T max was set at 50 minutes, as recommended previously (6) .
Genotyping Procedures. DNA was isolated from whole blood with a QIAamp DNA Blood Midikit or from plasma with a QIAamp UltraSens Virus kit (Qiagen, Valencia, CA). DNA was amplified with PCR-based techniques. RFLP analysis was used to identify variations in the CYP3A4 (CYP3A4*1B, CYP3A4*6, CYP3A4*17, and CYP3A4*18) and CYP3A5 (CYP3A5*3C and CYP3A5*6) genes as described previously (11, 12) . For the CYP3A5*6 assay, samples were first analyzed for the CYP3A5*3C variant. Subsequently, only samples with at least one wild-type allele (*1/*1 and *1/*3 genotypes) were then analyzed for the CYP3A5*6 variant. All variant alleles found were confirmed by PCR-RFLP.
Statistical Considerations. Erythromycin breath test parameters were summarized as the mean, 95% confidence level, and range. Values for age were grouped as Ͻ70 and Ն70 (elderly) years. Values for body surface area and ␣-1 acid glycoprotein were grouped as follows: lower quartile, interquartile range, and upper quartile. Values for BMI were grouped as follows: Ͻ25 (normal weight), 25 to 29.9 (overweight), and Ն30 (obese). For continuous variables, nonparametric tests were used to compare mean values between different groups. When three or more groups were compared, a trend test was used (13) . Univariate correlation analysis was performed with the software program JMP version 3.2.6 (SAS Institute, Carey, NC). Although this analysis was mainly exploratory in intent, an adjustment was used to evaluate the significance of the multiple comparisons (five demographic characteristics and two genotypes). P values (two-sided) of Ͻ0.007 were regarded as statistically significant, and those Ͻ0.05 were considered a trend.
Multiple linear regression models were then used to assess the influence of age, body size (body surface area and BMI), liver function group, sex, ␣-1 acid glycoprotein, and CYP3A4 and CYP3A5 genotypes (predictor variables) on erythromycin breath test parameters (outcome variables). Age, body size, and ␣-1 acid glycoprotein were included as continuous variables; liver function group, sex, and CYP3A4 and CYP3A5 genotypes were included as categorical variables. Regression coefficients, 95% confidence intervals, and the associated P values were determined from the multiple linear regression modeling.
Stepwise backward elimination was performed to systematically exclude the least significant factors until the P value was Ͻ0.05. Multiple linear regression modeling was performed with the software program Stata, version 8.2 (Stata Corp., College Station, TX). For this analysis, the a priori level of significance was set at P Ͻ 0.05.
To determine the power to detect differences in CYP3A activity between different genotypes, a mean CYP3A activity (C 20min ) of 0.050% dose/min was used; this value was estimated from the presently studied group of cancer patients. In this group of patients, the SD of the expected differences of the two measurements was estimated to be 0.023% dose/min. The calculation was designed to detect an effect size of 0.025/0.023, where 0.025 is 50% of the mean CYP3A activity, and was based on a two-sided analysis, a sample size of 118 for CYP3A4*1B and 121 for CYP3A5*3C, and a significance level (␣) of 0.05 (5%). This statistical analysis was performed in the SISABinomial program (D. G. Uitenbroek, Hilversum, the Netherlands, 1997).
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RESULTS
Patients.
A total of 134 patients with cancer (62 females and 72 males) was included in this study ( Table 1 ). The median age was 61 years (range, 26 to 83 years), and 35 patients were Ն70 years. The majority of the population was white (European and European American) and seven patients were black (African American). Twenty patients were obese with a BMI Ն 30 kg/m 2 , and 32 patients had elevated liver function tests as defined for liver function group 2 (n ϭ 14), liver function group 3A (n ϭ 12), and liver function group 3B (n ϭ 6).
CYP3A Phenotype. The erythromycin breath test parameters were similar between the two study protocols: C 20min , 0.047 versus 0.048% dose/min (P ϭ 0.5615); AUC 0 -40min , 1.57 versus 1.69% dose/min (P ϭ 0.3294); and 1/T max , 0.062 versus 0.061 min -1 (P ϭ 0.2036); the central tendency and variance for these parameters were similar for data obtained from study protocol 1 (n ϭ 81) and study protocol 2 (n ϭ 53; Fig. 1 ). C 20min and AUC 0 -40min were highly correlated (R 2 ϭ 0.9657, P Ͻ 0.0001), whereas C 20min and 1/T max were less strongly correlated (R 2 ϭ 0.2578, P Ͻ 0.0001). In this population of cancer patients, interpatient variation in CYP3A activity was 50-and 10-fold as determined by values for AUC 0 -40min and 1/T max , respectively ( Fig. 1 and Table 2 ); this extent of interpatient variation was observed in patients with normal liver function as defined for liver function group 1. In consideration of patients with ERMBT parameter values at the extreme of the population, values for AUC 0 -40min and 1/T max for 95% of the population varied 14-fold (0.240 -3.30% dose/min) and 5-fold (0.020 to 0.10 min Ϫ1 ), respectively. CYP3A Genotype. Genotype and allele frequencies for four variants of CYP3A4 and two variants of CYP3A5 are summarized in Table 3 . All patients were wild-type for CYP3A4*6 (n ϭ 120), CYP3A4*17 (n ϭ 116), and CYP3A4*18 (n ϭ 122). For CYP3A4*1B, 106 patients were wild-type, 12 patients were heterozygous variant, and no patients were homozygous variant; 4 of 6 African Americans were heterozygous variant. For CYP3A5*3C, 2 patients were wild-type (*1/*1 genotype), 19 patients were heterozygous variant (*1/*3 genotype), and 100 patients were homozygous variant (*3/*3 genotype); 6 of 6 African Americans and 15 of 115 white subjects carried at least one *1 allele, respectively. The allele frequencies for CYP3A4*1B and CYP3A5*3C were in Hardy-Weinberg equilibrium. For CYP3A5*6, no patients were homozygous variant, and two were heterozygous variant (both heterozygotes were African American). Because of the low frequency of variants, genotypes for CYP3A4*6, CYP3A4*17, CYP3A4*18, and CYP3A5*6 were not included for genotype-phenotype association analysis as shown below.
Predictors of CYP3A Activity. CYP3A activity was reduced by ϳ50% in patients in liver function groups 3A and 3B (P Ͻ 0.001 for trend; Table 2 ). Consequently, for univariate association analysis between patient characteristics, CYP3A4/5 genotype, and CYP3A activity, patients in liver function groups 3A and 3B were excluded (Table 4) . CYP3A activity was similar in patients ages Ն 70 years compared with those Ͻ 70 years of age (P Ͼ 0.3726) at the upper extreme of BSA values (P Ͼ 0.092 for trend) and in obese patients (P Ͼ 0.162 for trend). CYP3A, as determined from the parameter AUC 0 -40min , was higher in females compared with male patients (1.92 versus 1.56% dose/min; P ϭ 0.0063); the erythromycin breath test parameters C 20min and 11 Internet address: http://home.clara.net/sisa/samsize.htm. 1/T max showed a trend for difference according to sex (P ϭ 0.0120 and 0.0491, respectively). Analysis of ␣-1 acid glycoprotein values in the three-quartile groups showed that only the erythromycin breath test parameter 1/T max was associated with ␣-1 acid glycoprotein (lower quartile, mean ϭ 0.077 min -1 ; interquartile range, mean ϭ 0.065 min -1 ; upper quartile, mean ϭ 0.055 min -1 ; P ϭ 0.001 for trend). Linear correlation between 1/T max and ␣-1 acid glycoprotein concentration showed a weak but significant association (R 2 ϭ 0.08945, P ϭ 0.0015), with lower 1/T max values at higher ␣-1 acid glycoprotein concentrations. There was a trend for lower CYP3A activity in patients with ␣-1 acid glycoprotein concentrations in the upper quartile compared with patients with ␣-1 acid glycoprotein values below the upper quartile (75% quartile; C 20min , 0.053 versus 0.042% dose/min, P ϭ 0.0481; AUC 0 -40min , 1.82 versus 1.43% dose/min, P ϭ 0.0560; 1/T max , 0.067 versus 0.055 min -1 , P ϭ 0.0057). CYP3A activity was not associated with CYP3A5*3C genotype (P Ͼ 0.2954; power ϭ 94%), as illustrated in Fig. 2 or CYP3A4*1B genotype (P Ͼ 0.2719; power ϭ 69%).
Because body surface area and BMI were highly correlated (R 2 ϭ 0.3794, P Ͻ 0.0001), only body surface area was included as a body size indicator in the multivariate models. In addition, because of the small number of observations and similar values for CYP3A activity in liver function groups 3A and 3B, these two groups were combined for multiple linear regression analysis. Observations for body surface area, sex, liver function group, and ␣-1 acid glycoprotein concentration were available for 126 patients. When CYP3A4 and CYP3A5 genotypes were added to the model, observations were available for 115 individuals; because no association was noted between CYP3A4*1B or CYP3A5*3C genotypes and erythromycin breath test parameters values (P Ͼ 0.2719; Table 4 ), CYP3A4 and CYP3A5 genotypes were not included in the multiple linear regression analysis. After stepwise backward deletion, age, body surface area, and sex were removed from the final model for the three erythromycin breath test outcome variables (C 20min , AUC 0 -40min , and 1/T max ). ␣-1 Acid glycoprotein and liver function group 3A/B were predictors of CYP3A activity, where the multivariate model explained ϳ18% of overall variation in CYP3A activity (Table 5 ). Both ␣-1 acid glycoprotein and liver dysfunction were negatively correlated with CYP3A activity. Liver impairment had the most profound effect on CYP3A activity (coefficient ϭ Ϫ0.798; P Ͻ 0.001); assuming an average AUC 0 -40min value of 1.61% dose/min, this represents a 50% reduction in CYP3A activity, which is consistent with that observed from the univariate association analysis (Table 2) .
DISCUSSION
In adults, CYP3A4 and CYP3A5 are the most important among the four CYP3A subfamily members for CYP3A-mediated drug metabolism (14 -16) , and because of the genetic diversity in the genes encoding these proteins (17) , genotyping for CYP3A4 and CYP3A5 variants may be useful for prediction of total hepatic CYP3A activity. The CYP3A5 protein isoform is known to be expressed in only 10 to 30% of white subjects because of a splice variant in intron 3 of the CYP3A5 gene at nucleotide position 6986 (CYP3A5*3C; refs. 18, 19) . Approximately 85 to 95% of white subjects and 35 to 45% black subjects are homozygous for CYP3A5*3C and thus deficient in CYP3A5 (18 -20) . Another splice variant (CYP3A5*6), which is observed in black populations also, results in lack of CYP3A5 expression (18, 19) . Genetic differences may also explain 60 to 90% of the observed variation in CYP3A4-mediated drugmetabolizing capacity between patients (17). Over 30 single nucleotide polymorphisms in CYP3A4 have been published, representing alleles CYP3A4*1 to CYP3A4*19, most of which are very rare and unlikely to impact on CYP3A4 activity in vivo. The best characterized variant, a promoter variant with an A to G transition at nucleotide Ϫ392 (CYP3A4*1B), was shown in vitro to have increased transcriptional activity (17, 21) This variant exhibits interethnic variation with allele frequencies of 2 to 10% in white subjects and 35 to 84% in black subjects (18, (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) . Three other CYP3A4 polymorphisms (CYP3A4*6, CYP3A4*17, and CYP3A4*18) have been shown in vitro to result in functional changes in CYP3A activity (39, 40) .
In the present study, no association was noted between the CYP3A5*3C variant and CYP3A activity. This is similar to findings in healthy subjects with the CYP3A phenotyping probes midazolam (30, 35, 41, 42) , erythromycin (35, 36) , and nifedipine (36, 43) . One recent study involving a predominantly white population of 67 cancer patients observed 1.7-fold higher midazolam clearance in 9 patients with the *1/*3 genotype at the CYP3A5*3C allele compared with 58 patients with the *3/*3 genotype (44) . These data are not consistent with the present study with the erythromycin breath test involving 18 patients with the *1/*1 or *1/*3 genotype and 85 patients with the *3/*3 genotype (Table 4 ). The contradictory results could be explained by consideration of the probe drug used to assess CYP3A activity: erythromycin is reported to be a CYP3A4 substrate but a poor substrate for CYP3A5, whereas midazolam is a substrate for both CYP3A4 and CYP3A5 (3). However, studies in healthy subjects involving populations of similar sample size and diverse race/ethnicity, including African Americans (35), Asians (41, 45) , and whites (35) , showed no association between CYP3A5*3C genotype and midazolam clearance. One additional factor to consider regarding the lack of observed genotype-phenotype relationships for CYP3A is that these studies may have involved the administration of probe drug doses that produced plasma concentrations well below CYP3A4 enzyme saturation, as is the case for erythromycin dose used in the erythromycin breath test. A recent study showed a dose-dependent association between CYP3A5*3C genotype and plasma concentrations of ABT-773, where drug exposure was higher in No association was observed between the CYP3A4*1B variant and CYP3A activity, which was also consistent to that observed in healthy subjects with the CYP3A-phenotyping probes midazolam (30, 35, 42) , erythromycin (35) , and nifedipine (36) . Because of the lack of CYP3A4*6, CYP3A4*17, and CYP3A4*18 variants in the present study, these polymorphisms most likely have no relevance to CYP3A activity in white populations. The data presented on the association between CYP3A4 and CYP3A5 genotype and CYP3A activity adds to the list of evidence that the chosen single nucleotide polymorphisms are not causative for altered in vivo activity.
In the current study, CYP3A activity was unaltered in patients with mild elevations in liver function tests (group 2) but was reduced by ϳ50% in patients with moderate to severe liver impairment as defined for liver function groups 3A and 3B. Interestingly, categorization of liver function tests for group 3A was described by Bruno et al. (47, 48) for prediction of docetaxel clearance; patients with total bilirubin Ͻ 1.5ϫ upper limit of normal but elevations in liver transaminases (Ն1.5ϫ upper limit of normal) concurrent with elevated alkaline phosphatase (Ն2.5ϫ upper limit of normal) were shown to have reduced docetaxel clearance by 25%. The same categorization of liver function tests to describe liver impairment was also associated with reduced CYP3A activity in the present study. However, liver function tests are not accurate in prediction of CYP3A activity as patients with the lowest CYP3A activity had normal liver function (group 1). The use of the erythromycin breath test as a phenotypic probe has been questioned as conflicting reports on its ability to predict the total body clearance of probe drugs have been reported (4, 49) , although a study in 20 patients with sarcoma showed that the erythromycin breath test predicted docetaxel clearance in those with greatly reduced drug clearance (50) . Nevertheless, despite the limitations of the erythromycin breath test, results of the present study demonstrate that patients with low breath levels of 14 CO 2 have low CYP3A function and are likely to have reduced CYP3A-mediated drug clearance.
Because of large variations in concentrations of the acute phase reactant protein ␣-1 acid glycoprotein in cancer patients (7-fold), it has been hypothesized that decreased hepatic clearance by CYP3A in some individuals might be a consequence of an inflammatory response (51) . In the present study, ␣-1 acid glycoprotein was associated with CYP3A activity in both univariate and multiple regression analysis. However, combined with liver function, only 18% of CYP3A variation was explained by these two variables. Previously, a better correlation was observed between C-reactive protein and CYP3A activity compared with ␣-1 acid glycoprotein (6) . Assessment of Creactive protein, a more specific marker of inflammation, was not measured in this study, but it may have accounted for more of the variation in CYP3A activity in this population of cancer patients.
In the present study, body surface area and BMI were not correlated with CYP3A activity, consistent with poor correlations between body size parameters and the clearance of drugs metabolized by CYP3A (1, 52) . However, alterations in anticancer drug clearance have been noted in obese patients and those at the upper extreme of body size, such as for doxorubicin and docetaxel (52) . Other factors in addition to CYP3A activity, such as changes in volume of distribution, may contribute to altered drug disposition in obese patients (53) .
The influence of age on the expression and activity of drug-metabolizing enzymes remains controversial with reports describing either a decline in activity or no change in activity in elderly patients (54 -56) . In the current study, CYP3A activity was shown to be similar in patients ages Ͻ 70 years (n ϭ 99) and Ն 70 years (n ϭ 35). Prior in vitro studies have suggested an age related decline in CYP3A activity (57) . However, our results are consistent with an in vivo study that applied the erythromycin breath test as a phenotyping probe of CYP3A-mediated drug clearance, where no decrease in CYP3A activity was observed as a function of age in 39 older hypertensive men (56) .
Many drugs that are substrates of CYP3A show higher clearance in women than in men (58 -60) . In concordance with this observation, previous studies have shown ϳ20 to 25% higher CYP3A activity in females than males with the erythromycin breath test (8, 35, 54) . However, it has been suggested that this observation is due to one limitation of the erythromycin breath test, the assumption that individuals (both females and males) produce 5 mmol CO 2 /min/m 2 at rest (10) . Reanalysis of previously published data evaluating the calculation of CO 2 output in different populations revealed a ϳ20% lower rate of CO 2 production in females, which is consistent with the 20 to 25% difference observed in erythromycin breath test results between the two sexes (10) . In the present study, females were found to have ϳ15 to 20% higher CYP3A activity than males in univariate analysis, but the association was not significant in multiple regression analysis. A recent study of 94 surgical liver samples found 2-fold higher CYP3A4 protein content and higher expression of CYP3A4 mRNA transcripts in female compared with male samples (61) . In contrast, other studies in human livers observed no sex differences in CYP3A (62, 63) . Regardless of apparent sex-related differences in CYP3A activity, the same range of wide interpatient variation in CYP3A activity was observed in both female and male cancer patients ( Table 4 ), indicating that dosing strategies for drugs cleared by CYP3A should focus on the individual and not necessarily sex.
One additional factor to consider is the influence of drug interactions on interpatient variation in CYP3A activity. There is considerable motivation for understanding adverse drug interactions with anticancer agents because of their narrow therapeutic index. Usually, such interactions arise as a result of altered pharmacokinetics of the drugs involved. Careful examination of the concomitant drug profiles for drugs that are substrates, inhibitors, or inducers of CYP3A did not reveal an association with results of the erythromycin breath test in the entire population or upon analysis of values in the lower and upper quartiles. In addition, many botanical dietary supplements contain pharmacologically active phytochemicals, and to date, numerous herb-drug interactions have been described in the medical literature (64, 65) and are most commonly pharmacokinetic in nature. Availability of this type of information is particularly relevant to the treatment of cancer patients who are known to take a wide variety of complementary and alternative medicine concomitantly with their chemotherapeutic regimen (66) . However, little information is available from prospective evaluation of drug interactions between complementary and alternative medicine and anticancer agents to help guide the use of complementary and alternative medicine in cancer patients receiving chemotherapy (67) . To complicate matters additionally, the current study protocol conducted in the United States and the Netherlands included a list of complementary and alternative medicine to review with each patient before study enrollment; however, of 81 patients enrolled on this protocol, no patients were documented to be taking complementary and alternative medicine. Because various studies have documented the extensive use of complementary and alternative medicine in cancer patients and that Ͻ40% of patients disclose their herbal supplement usage to healthcare providers (68), ways to ensure accurate and complete documentation of complementary and alternative medicine use by patients enrolled to clinical trials is urgently needed.
In conclusion, the current investigation has identified liver function and ␣-1 acid glycoprotein concentration in plasma as significant predictors of CYP3A activity in patients with cancer. However, these two factors combined explained only 18% of overall variation in CYP3A activity. Consideration of additional factors, including C-reactive protein, as well as the concomitant use of other drugs, food constituents, and complimentary and alternative medicine with inhibitory and inducible effects on CYP3A, may account for variation in CYP3A activity in cancer patients. In light of the present results noting no significant genotype-phenotype associations between the chosen single nucleotide polymorphisms and CYP3A activity with the erythromycin breath test, CYP3A phenotyping strategies should provide the most clinically relevant information reflecting the combined effects of genetic, environmental, and endogenous/ physiologic factors on drug disposition and effects.
